Morgan Stanley Has $1.49 Million Stake in Natus Medical Incorporated (NASDAQ:NTUS)


Share on StockTwits

Morgan Stanley decreased its holdings in Natus Medical Incorporated (NASDAQ:NTUS) by 12.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 87,089 shares of the company’s stock after selling 12,082 shares during the quarter. Morgan Stanley owned 0.26% of Natus Medical worth $1,492,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NTUS. Prospera Financial Services Inc acquired a new stake in Natus Medical in the 3rd quarter worth about $39,000. Pathstone Family Office LLC bought a new position in Natus Medical in the 3rd quarter valued at about $101,000. BNP Paribas Arbitrage SA increased its holdings in Natus Medical by 246.9% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,534 shares of the company’s stock valued at $146,000 after buying an additional 6,074 shares during the period. Louisiana State Employees Retirement System increased its holdings in Natus Medical by 70.3% in the 3rd quarter. Louisiana State Employees Retirement System now owns 15,700 shares of the company’s stock valued at $269,000 after buying an additional 6,480 shares during the period. Finally, GSA Capital Partners LLP bought a new position in Natus Medical in the 3rd quarter valued at about $280,000. Institutional investors and hedge funds own 80.92% of the company’s stock.

Shares of Natus Medical stock opened at $25.02 on Thursday. The firm has a market capitalization of $847.38 million, a PE ratio of -45.49 and a beta of 0.72. The company has a current ratio of 2.02, a quick ratio of 1.41 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $21.19 and its 200 day moving average is $19.54. Natus Medical Incorporated has a 1 year low of $16.38 and a 1 year high of $34.67.

Natus Medical (NASDAQ:NTUS) last posted its earnings results on Thursday, October 29th. The company reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.08. Natus Medical had a negative net margin of 4.33% and a positive return on equity of 3.87%. The firm had revenue of $102.80 million for the quarter, compared to analyst estimates of $94.40 million. During the same period in the previous year, the firm posted $0.36 EPS. The company’s revenue for the quarter was down 16.7% compared to the same quarter last year. As a group, research analysts anticipate that Natus Medical Incorporated will post 0.25 earnings per share for the current year.

NTUS has been the topic of several recent analyst reports. BidaskClub raised shares of Natus Medical from a “hold” rating to a “buy” rating in a report on Saturday, January 9th. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Tuesday, November 3rd. TheStreet raised shares of Natus Medical from a “d+” rating to a “c-” rating in a report on Wednesday, January 6th. Finally, ValuEngine raised shares of Natus Medical from a “hold” rating to a “buy” rating in a report on Thursday, October 1st. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Natus Medical currently has an average rating of “Buy” and a consensus price target of $20.00.

Natus Medical Profile

Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.

Featured Story: Exchange-Traded Funds (ETFs)

Want to see what other hedge funds are holding NTUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:NTUS).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:NTUS)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.